The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
acute decompensated heart failure
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)